Applications of N-Phenyl-2-Deoxy-D-Glucosylamine in Industrial Manufacturing

N-Phenyl-2-Deoxy-D-Glucosylamine supports a wide range of specialty production environments as a valuable intermediate and modifier, used across advanced sectors where specific glycosylation or linkage properties are required. As the direct manufacturer, we help clients across distinct industries integrate this compound with precise specification adherence, process control, and compliance to international standards.

1. Active Pharmaceutical Ingredient (API) Synthesis in Glycosylated Drug Development

Leading pharmaceutical producers incorporate N-Phenyl-2-Deoxy-D-Glucosylamine into glycosylation steps for next-generation small molecule APIs where glycosylamine cores are essential. The unique deoxy and phenyl-protected functional groups allow for controlled coupling reactions and enhance metabolite profiles compared to standard glucosyl donors. Operations require consistent purity and reliable integration in scale-up, as well as full traceability throughout GMP processing lines.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• US FDA 21 CFR Parts 210/211 cGMP
• European Pharmacopoeia Monographs (e.g., 2.2.32, 2.2.46 for glycosyl compounds)
• USP <1078> Good Pharmaceutical Water and process validations

Typical usage ratio

• 0.2%–1.5% w/w relative to base API batch; ratio optimizes for target glycosyl conjugation, adjusted according to yield and downstream coupling efficiency.

Downstream process integration

• Added at protected glycosyl donor formation stage in multi-step chemical synthesis
• Serves as base substrate for enzymatic glycosylation or reductive amination coupling
• Subject to HPLC QC prior to scale-up

Final product types

• Oral antidiabetic drugs with glycosylated actives
• Novel glycoconjugated antivirals
• Specialty anti-inflammatory drugs with sugar modifications

2. Specialty Glycoside Intermediate for High-Value Agrochemical Formulations

Agrochemical formulators use this compound when synthesizing novel glycoside-based active agents for selective plant protection. Its role as a building block, due to stable phenyl-protected glucosylamine structure, enables the creation of unique molecules with highly controlled sugar-amino linkages, crucial in developing targeted pesticide molecules designed to minimize resistance and environmental impact.

Industry compliance standards

• FAO/WHO Codex Alimentarius for pesticide residue compliance
• ISO 9001:2015 certified manufacturing for agricultural intermediates
• REACH Registration for European market
• China National Standard GB/T 21852 for agrochemical raw material quality

Typical usage ratio

• 0.5%–2.0% w/w in intermediate synthesis stages, scaled based on the downstream active ingredient yield target

Downstream process integration

• Incorporated during glycosylation coupling under controlled temperature and pH
• Purified via column chromatography before final pesticide assembly
• Residue analysis performed for regulatory batch release

Final product types

• Targeted systemic fungicides
• Selective herbicide products
• Modern insecticidal actives with modified sugar moieties

3. Diagnostic Enzyme Substrate Manufacturing for Analytical Reagents

Producers specializing in biochemical diagnostics employ N-Phenyl-2-Deoxy-D-Glucosylamine as a precursor for synthetic enzyme substrates used in quantitative assays, especially for rare glycosidase detection. Its deoxy modification enables the synthesis of chromogenic or fluorogenic substrates that support high specificity and reduced interference in clinical and research applications.

Industry compliance standards

• ISO 13485:2016 for in vitro diagnostic device manufacturing
• CLSI EP05 for protocol validation
• European IVD Directive 98/79/EC
• RoHS Directive for electronic and reagent component safety

Typical usage ratio

• 0.3%–0.8% w/w in precursor feed per batch, fixed according to the scale of substrate output and testing sensitivity requirements

Downstream process integration

• Integrated during protected sugar-amino group synthesis under mild conditions
• Subsequently derivatized with chromogenic or fluorescent tags
• QC performed on substrate activity and purity prior to reagent kit formulation

Final product types

• Chromogenic substrates for β-glycosidase assays
• Fluorogenic glycosidic reagents for high-throughput screening kits
• Specialty biochemical diagnostic panels for hospital laboratories

4. Glycosylated Surface Modifier for Biomedical Material Coatings

Biomedical material producers rely on this compound in advanced coatings to impart non-immunogenic glycosyl layers on device surfaces. Phenyl-deoxy-glycosylamine units support covalent attachment to polymers, providing steric protection and reducing undesirable protein adsorption, which is critical for blood-contact medical devices and biocompatible implants.

Industry compliance standards

• ISO 10993 for biological evaluation of medical devices
• USP <88> Class VI plastics testing
• EU MDR 2017/745 compliance for implantables
• ISO 13485 Quality Management for Medical Devices

Typical usage ratio

• 1.2%–4.0% w/w in surface treatment mixture, based on desired surface density and polymer compatibility. Proportion tuned for batch process scale.

Downstream process integration

• Added to grafting solution prior to surface activation with carbodiimide or similar chemistry
• Cured under controlled temperature and humidity to achieve uniform linkage
• Surface analytics carried out for adsorption resistance validation

Final product types

• Blood-contact catheters and stents
• Implantable mesh and barrier materials
• Disposable surgical tools with anti-thrombogenic coatings

5. Carbohydrate Building Block for Oligosaccharide-Based Vaccine Antigen Production

Vaccine manufacturers make use of this specialty glycosylamine as a protected intermediate in the stepwise chemical assembly of immunogenic oligosaccharide antigens for conjugate vaccines. Its selective reactivity and stability in coupling reactions support precise control over antigenic structure, which is vital for consistent immunoreactivity and batch reproducibility.

Industry compliance standards

• WHO Technical Report Series for Vaccine Manufacturing
• cGMP as per 21 CFR Part 600–680 (Biological Products)
• European Pharmacopoeia 01/2024:20701 on vaccine antigens
• GMP Annex 2 – Manufacture of Biological Medicinal Substances

Typical usage ratio

• 0.6%–1.3% w/w, adjusted according to individual oligosaccharide sequence and conjugation efficiency targeting defined epitope length

Downstream process integration

• Introduced at the monosaccharide activation stage for stepwise chain elongation
• Purified prior to final deprotection and conjugation with carrier proteins
• Validated for residual solvent and endotoxin removal before downstream fill/finish

Final product types

• Bacterial conjugate vaccines (e.g., pneumococcal, meningococcal)
• Synthetic oligosaccharide antigens for emerging vaccine candidates
• Immunodiagnostic test reagents